๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial

โœ Scribed by Wang, M; Fowler, N; Wagner-Bartak, N; Feng, L; Romaguera, J; Neelapu, S S; Hagemeister, F; Fanale, M; Oki, Y; Pro, B; Shah, J; Thomas, S; Younes, A; Hosing, C; Zhang, L; Newberry, K J; Desai, M; Cheng, N; Badillo, M; Bejarano, M; Chen, Y; Young, K H; Champlin, R; Kwak, L; Fayad, L

Book ID
120939046
Publisher
Nature Publishing Group
Year
2013
Tongue
English
Weight
817 KB
Volume
27
Category
Article
ISSN
0887-6924

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Oral lenalidomide with rituximab in rela
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
โœ Wang, M; Fowler, N; Wagner-Bartak, N; Feng, L; Romaguera, J; Neelapu, S S; Hagem ๐Ÿ“‚ Article ๐Ÿ“… 2013 ๐Ÿ› Nature Publishing Group ๐ŸŒ English โš– 817 KB

Lenalidomide-rituximab therapy is effective in grade 1-2 follicular and mantle cell lymphoma, but its efficacy in diffuse large B-cell lymphoma (DLBCL), transformed large cell lymphoma (TL) and grade 3 follicular lymphoma (FLG3) is unknown. In this phase II trial, 45 patients with relapsed or refrac